Table 1.
Cox regression hazard analysis on the overall survival in the entire cohort
| Variables | N | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | ||
| Karyotypes | |||||
| Favorable | 22 | Reference | Reference | ||
| Intermediate | 69 | 1.380 (0.685–2.782) | 0.368 | 4.339 (1.559–12.076) | 0.005 |
| Unfavorable | 21 | 3.147 (1.433–6.909) | 0.004 | 7.024 (2.340–21.088) | 0.001 |
| Genetic alterations | |||||
| CEBPA* | 7 | 0.410 (0.100–1.679) | 0.215 | 0.378 (0.089–1.610) | 0.188 |
| DNMT3A | 14 | 0.460 (0.184–1.148) | 0.096 | 0.622 (0.188–2.051) | 0.435 |
| IDH2 | 14 | 0.481 (0.192–1.200) | 0.117 | 0.307 (0.083–1.135) | 0.077 |
| IDH1 | 4 | 0.771 (0.188–3.154) | 0.718 | 3.651 (0.747–18.858) | 0.110 |
| GATA2 | 7 | 0.839 (0.263–2.676) | 0.767 | 0.291 (0.055–1.530) | 0.145 |
| NPM1 | 17 | 0.945 (0.450–1.985) | 0.882 | – | – |
| WT1 | 13 | 0.987 (0.425–2.291) | 0.976 | 1.074 (0.438–2.635) | 0.876 |
| FLT3‐ITD | 24 | 1.223 (0.684–2.186) | 0.497 | – | – |
| ASXL1 | 18 | 1.242 (0.648–2.381) | 0.514 | 1.089 (0.524–2.264) | 0.819 |
| TET2 | 12 | 1.648 (0.784–3.462) | 0.188 | 3.740 (1.598–8.750) | 0.002 |
| RUNX1 | 7 | 1.815 (0.781–4.220) | 0.166 | 2.037 (0.821–5.050) | 0.125 |
| TP53 | 9 | 2.043 (0.816–5.113) | 0.127 | 1.916 (0.628–5.842) | 0.253 |
| PHF6 | 3 | 2.061 (0.645–6.584) | 0.223 | 6.016 (1.255–28.844) | 0.025 |
| KIT | 5 | 2.429 (0.965–6.117) | 0.060 | 12.131 (3.175–46.358) | <0.001 |
| U2AF1 | 3 | 4.293 (1.322–13.94) | 0.015 | 6.575 (0.987–43.815) | 0.052 |
| NPM + /FLT ‐ | 10 | 0.662 (0.240–1.824) | 0.425 | 0.225 (0.059–0.855) | 0.028 |
HR, hazard ratio; ITD, internal tandem duplication.
CEBPA*: CEBPA double mutation; NPM + /FLT ‐: NPM1 mutation/FLT3‐ITDnegative